MDRNA Inks Early-Stage Collaboration Related to miRNA Therapies

The arrangement will focus on the use of MDRNA's DiLA2 delivery technology with proprietary miRNAs in "experimental oncology models."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.